# Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

> **NCT01624805** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 140 (estimated)

## Conditions studied

- Aplastic Anemia
- de Novo Myelodysplastic Syndrome
- Myelodysplastic Syndrome
- Previously Treated Myelodysplastic Syndrome

## Interventions

- **BIOLOGICAL:** Anti-Thymocyte Globulin
- **DRUG:** Cyclosporine
- **BIOLOGICAL:** Filgrastim
- **DRUG:** Methylprednisolone
- **BIOLOGICAL:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT01624805
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2012-06-25
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01624805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01624805, "Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01624805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*